Zai Lab (ZLAB) Lowered to “Buy” at BidaskClub

Zai Lab (NASDAQ:ZLAB) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

A number of other equities analysts have also commented on the stock. ValuEngine upgraded shares of Zai Lab from a “hold” rating to a “buy” rating in a report on Thursday, February 7th. Credit Suisse Group assumed coverage on shares of Zai Lab in a report on Tuesday, January 29th. They issued an “outperform” rating and a $34.70 target price on the stock. Zacks Investment Research upgraded shares of Zai Lab from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Sunday, January 6th. Finally, Jefferies Financial Group assumed coverage on shares of Zai Lab in a report on Wednesday, November 21st. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $33.93.

Shares of NASDAQ:ZLAB opened at $28.57 on Tuesday. The firm has a market cap of $1.78 billion, a PE ratio of -12.31 and a beta of 1.20. Zai Lab has a 52 week low of $14.29 and a 52 week high of $33.86.



A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC increased its stake in Zai Lab by 14.9% in the third quarter. FMR LLC now owns 5,810,571 shares of the company’s stock valued at $113,190,000 after purchasing an additional 755,144 shares in the last quarter. Segantii Capital Management Ltd increased its stake in Zai Lab by 348.8% in the third quarter. Segantii Capital Management Ltd now owns 2,398,797 shares of the company’s stock valued at $46,729,000 after purchasing an additional 1,864,352 shares in the last quarter. Bamco Inc. NY increased its stake in Zai Lab by 1,955.8% in the third quarter. Bamco Inc. NY now owns 1,900,431 shares of the company’s stock valued at $37,020,000 after purchasing an additional 1,807,990 shares in the last quarter. Vanguard Group Inc. bought a new stake in Zai Lab in the third quarter valued at $14,955,000. Finally, Vanguard Group Inc bought a new stake in Zai Lab in the third quarter valued at $14,955,000. 34.48% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.

Recommended Story: LIBOR

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply